ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1261

Molecular Analysis of Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis: Targeting Endothelin-1 Receptor to Control Proliferation

Alexis Regent1, Kim Heang Ly2, Matthieu Groh3, Chabha Khifer4, Sebastien Lofek5, Mathieu Tamby6, Guilhem Clary7, Philippe Chafey7, Véronique Baud8, Cédric Broussard9, Christian Federici7, Francois Labrousse10, Laura Mesturoux11, Claire Le Jeunne12, Elisabeth Vidal13, Antoine P. Brezin14, Veronique Witko-Sarsat15, Loïc Guillevin12 and Luc Mouthon15, 1Service de médecine interne, Hôpital Cochin, Paris, France, 2CHU Dupuytren, Limoges, Limoges, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 4Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, Paris, France, 5Université Paris Descartes, Paris, France, 6Institut Cochin, U1016, Paris, France, 7Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, 8Institut cochin, U1016, Paris, France, 9Inserm U 567, CNRS UMR 8104, Cochin Institute, Paris, France, 10Department of Pathology, Limoges University Hospital, Limoges, France, 11CHU Limoges, Limoges, France, 12Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 13Internal Medecine, Limoges hospital, Paris, France, 14Université Paris Descartes, Hôpital Cochin, Paris, France, 15Labex Inflamex, Université Sorbonne Paris Cité, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: giant cell arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Vascular remodeling play a major role in the pathophysiology of giant cell arteritis (GCA) and the mechanisms underlying it are poorly understood.

Methods:

Vascular smooth muscle cells (VSMC) were cultured from temporal artery biopsies (TAB) obtained from patients suspected of GCA: patients with biopsy proven GCA (TAB+-GCA), patients with biopsy-negative GCA (TAB–-GCA), and patients with another diagnosis than GCA (GCA-control). Two-dimension DIGE (2D-DIGE) and affymetrix chips were used in order to analyze proteomes and gene expression profile of VSMC from the different groups. Normal human aorta VSMC (HAoSMC) were used as control in proteomic experiments. Proliferation of VSMC was analysed using a BrdU proliferation assay ELISA kit. Immunohistochemistry with ET-1, ETAR and ETBR were also performed on temporal artery biopsies from TAB+-GCA and GCA-control patients.

Results:

2D-DIGE analysis of VSMC protein extracts revealed 16, 30 and 2 protein spots differentially expressed between TAB+-GCA and GCA-control patients, between TAB+-GCA and TAB–-GCA patients and between TAB–-GCA and GCA-control patients, respectively (fold change≥1.5 and p-value≤0.05). Among the 153 differentially expressed between VSMC from TAB+-GCA and HAoSMC, a lot of them were linked with endothelin-1.

Genes differentially expressed between VSMC from patients with TAB+-GCA, TAB–-GCA and GCA-control were involved in proliferation. Endothelin-1 was also identified as a link between genes of interest. Proliferation of VSMC from TAB+-GCA patients was reduced in the presence of macitentan, an endothelin receptor antagonist and its active metabolite and was not modified with bosentan or ambrisentan. Interestingly, in immunochemistry analysis, patients who had a transmural expression of endothelin-1 on TAB received a significantly increased glucocorticoid daily dose after a 6-month follow-up.

Conclusion:

Inhibition of the increased proliferation of VSMC during GCA with macitentan might represent a promising therapeutic approach in patients with GCA, in combination with glucocorticoids.


Disclosure: A. Regent, None; K. H. Ly, None; M. Groh, None; C. Khifer, None; S. Lofek, None; M. Tamby, None; G. Clary, None; P. Chafey, None; V. Baud, None; C. Broussard, None; C. Federici, None; F. Labrousse, None; L. Mesturoux, None; C. Le Jeunne, None; E. Vidal, None; A. P. Brezin, None; V. Witko-Sarsat, None; L. Guillevin, None; L. Mouthon, None.

To cite this abstract in AMA style:

Regent A, Ly KH, Groh M, Khifer C, Lofek S, Tamby M, Clary G, Chafey P, Baud V, Broussard C, Federici C, Labrousse F, Mesturoux L, Le Jeunne C, Vidal E, Brezin AP, Witko-Sarsat V, Guillevin L, Mouthon L. Molecular Analysis of Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis: Targeting Endothelin-1 Receptor to Control Proliferation [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/molecular-analysis-of-vascular-smooth-muscle-cells-from-patients-with-giant-cell-arteritis-targeting-endothelin-1-receptor-to-control-proliferation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-analysis-of-vascular-smooth-muscle-cells-from-patients-with-giant-cell-arteritis-targeting-endothelin-1-receptor-to-control-proliferation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology